ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2022

1:00PM-3:00PM: Abstract Number: 1490

High Throughput Transcriptomic Analysis of Peripheral Mononuclear Cells Identifies Molecular Alterations Associated with the Active Clinical Phenotype of Axial Spondyloarthritis

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster III

1:00PM-3:00PM: Abstract Number: 1181

Hippo Pathway Effectors Promote and Maintain Myofibroblast Differentiation and Endothelial-to-mesenchymal Transition in Systemic Sclerosis

Systemic Sclerosis and Related Disorders – Basic Science Poster

1:00PM-3:00PM: Abstract Number: 1299

Hitting the Target Together: Supporting Shared Decision-Making with Juvenile Idiopathic Arthritis (JIA) Patients Followed in the Out-Patient Rheumatology Setting at the Hospital for Sick Children

Measures and Measurement of Healthcare Quality Poster

1:00PM-3:00PM: Abstract Number: 1368

How Common Is the Coexistence of Juvenile Localized and Systemic Scleroderma? Results of a Multination Survey

Pediatric Rheumatology – Clinical Poster II: Connective Tissue Disease

1:00PM-3:00PM: Abstract Number: 1516

How Disease Activity Can Affect Workability in Spondyloarthropaties: A Monocentric Cohort Analysis

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster III

1:00PM-3:00PM: Abstract Number: 1495

How Does Body Mass Index Affect Secukinumab Treatment Outcomes and Safety in Patients with Ankylosing Spondylitis? – Real World Data from a German Observational Study

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster III

1:00PM-3:00PM: Abstract Number: 1497

How Does Time to Diagnosis and Gender Affect Treatment Outcomes in Patients with Ankylosing Spondylitis or Psoriatic Arthritis? – Real World Data from a German Observational Study with Secukinumab

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster III

1:00PM-3:00PM: Abstract Number: 1288

How Often Do We Provide Relevant and Patient Centric Discharge Instructions in Rheumatology? A Single Academic Center Clinic Experience

Measures and Measurement of Healthcare Quality Poster

1:00PM-3:00PM: Abstract Number: 1177

Identification of a New Type of Pro-phagocytic Macrophages in Patients with Systemic Sclerosis

Systemic Sclerosis and Related Disorders – Basic Science Poster

1:00PM-3:00PM: Abstract Number: 1394

Identification of Joint Locations in an Early Rheumatoid Arthritis Cohort as a Characteristic of Disease Severity: DATA from the ERA-UCLouvain Brussels Cohort

RA – Diagnosis, Manifestations, and Outcomes Poster III

1:00PM-3:00PM: Abstract Number: 1513

Identification of MRI Lesions Indicative of Spondyloarthritis Diagnosis from the Axial Spondyloarthritis International Society (ASAS) MRImagine Multi-Reader Scoring Dataset Using the Chi-Squared Automatic Interaction Detection Algorithm (CHAID)

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster III

1:00PM-3:00PM: Abstract Number: 1130

Identification of Novel Molecular Signatures Associated with the Therapeutic Response to DMARDs and TNFi Therapies in Rheumatoid Arthritis Patients Through High Throughput Proteomics

Genetics, Genomics and Proteomics Poster

1:00PM-3:00PM: Abstract Number: 1215

Identifying a Pain Signature in Classical Ehlers-Danlos Syndrome: Preliminary Results from Questionnaires and Experimental Pain Testing

Fibromyalgia and Other Clinical Pain Syndromes Poster

1:00PM-3:00PM: Abstract Number: 1161

IL-36-receptor Antagonist-Antibodies in Psoriasis and Psoriatic Arthritis

Spondyloarthritis Including PsA – Basic Science Poster

1:00PM-3:00PM: Abstract Number: 1245

Imaging Use and Medication Management in Giant Cell Arteritis

Imaging of Rheumatic Diseases Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].